Sage Journals: Discover world-class research

Abstract

Venlafaxine, a structurally novel antidepressant, belongs to a new generation of antidepressants the serotonin/noradrenaline reuptake inhibitors. In clinical trials, venlafaxine was found safe and effective in most patients. However, significant changes in vital signs (hyperand hypotension) and cardiac conduction abnormalities were observed in a few patients, notably in elderly patients. We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with venlafaxine, and developed acute myocardial ischaemia within the first week of treatment. This is the first report of a possible association between an acute cardiovascular event and venlafaxine. The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties.

Keywords

cardiotoxicity serotonin/noradrenaline reuptake inhibitors venlafaxine

Get full access to this article

View all access options for this article.

References

Baldessarini R J (1996) Drugs and the treatment of psychiatric disorders: psychosis and anxiety. In Hardman J H , Limbird L E (eds), Goodman and Gilman: the pharmacological basis of therapeutics, 9th edn, McGraw-Hill, London, pp. 399-430

Benkert O , Grunder G and Wetzel H (1997) Is there an advantage to venlafaxine in comparison with other antidepressants? Hum Psychopharmacol 12: 53-64

Chester A H , Allen S P , Tadjkarimi S , Yacoub M H (1993) Interaction between thromboxane A2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation 87: 874-880

Danjou P , Hackett D (1995) Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 10 (Suppl.): 15-20

Dierick M (1996) An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 8: 169-177

Dierick M , Ravizza L , Realini R , Martin A (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in out patients. Progr Neuropsychopharmacol Biol Psychiatry 20: 57-71

Ereshefsky L (1996) Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 16 (Suppl.): 37S-53S

Feighner J P (1995) Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 56: 574-579

Fricchione G L , Woznicki R M , Klesmer J , Vlay S C (1993) Vasoconstrictive effects and SSRIs. J Clin Psychiatry 54: 71-72

10.

Gershon M D (1991) Serotonin, its role and receptors in enteric neurotransmission. In Schwarcz R (ed.), Kynurenine and serotoninergic pathways. Advances in experimental medicine and biology, vol. 294. Plenum Press, New York, pp. 221-230

11.

Grunder G , Wetzel H , Schlosser R , Benkert O (1996) Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24 hour monitoring. Pharmacopsychiatry 29: 72-78

12.

Holliday S M , Benfield P (1995) Venlafaxine-a review of its pharmacology and therapeutic potential in depression. Drugs 49: 1-15

13.

Khan A , Rudolph R , Baumel B , Ferguson J , Ryan P Shirvastava R (1995) Venlafaxine in depressed geriatric outpatients: an openlabel study. Psychopharmacol Bull 31: 753-758

14.

Muth E A , Moyer J A , Haskins J T , Andree T H , Husbands G E M (1991) Biochemical, neurophysiological and behavioral effects of Wy-45233 and other identified metabolites of the antidepressant venlafaxine. Drug Develop Res 23:191-199

15.

Skop B P , Brown T M (1996) Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 7: 12-16

16.

Shader R I , Fogelman S M , Greenblatt D J (1997) Editorial: newer antidepressants: hypotheses and evidence. J Clinical Psychopharmacol 17: 1-3

17.

Wyeth-Ayerst Laboratories (1995) Product information/data on file. Wyeth-Ayerst Laboratories, Philadelphia, PA

18.

Zimmer B , Kant R , Zeiler D , Brilmyer, M (1997) Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders. Int J Psychiatry Med 27(4): 353-364

An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms

Abstract

Keywords

Get full access to this article

References